VERACYTE, INC. Net Income (Loss) Available to Common Stockholders, Diluted
VERACYTE, INC. (VCYT) reported Net Income (Loss) Available to Common Stockholders, Diluted of $25.49 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-07-31.
Financial Statements › Income Statement › Net Income
us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted · last filed 2026-07-31
- VERACYTE, INC. net income (loss) available to common stockholders, diluted for the quarter ending 2026-06-30 was $25.49M.
- VERACYTE, INC. net income (loss) available to common stockholders, diluted for the quarter ending 2026-03-31 was $28.71M, a 307.36% increase year-over-year.
- VERACYTE, INC. net income (loss) available to common stockholders, diluted for the quarter ending 2025-12-31 was $41.15M, a 704.79% increase year-over-year.
- VERACYTE, INC. net income (loss) available to common stockholders, diluted for the quarter ending 2025-09-30 was $19.14M, a 26.28% increase year-over-year.
- VERACYTE, INC. net income (loss) available to common stockholders, diluted for fiscal 2025 was $66.35M, a 174.89% increase from fiscal 2024.
- VERACYTE, INC. net income (loss) available to common stockholders, diluted for fiscal 2024 was $24.14M.
- VERACYTE, INC. net income (loss) available to common stockholders, diluted for fiscal 2023 was -$74.40M.
- VERACYTE, INC. net income (loss) available to common stockholders, diluted for fiscal 2022 was -$36.56M.
| Period end | Net Income (Loss) Available to Common Stockholders, Diluted 3 month | Net Income (Loss) Available to Common Stockholders, Diluted 6 month | Net Income (Loss) Available to Common Stockholders, Diluted 9 month | Net Income (Loss) Available to Common Stockholders, Diluted 12 month |
|---|---|---|---|---|
| 2026-06-30 | $25.49M 10-Q · filed 2026-07-31 | $54.20M 10-Q · filed 2026-07-31 | $95.35M derived: sum of 3 quarters · filed 2026-07-31 | $114.48M derived: sum of 4 quarters · filed 2026-07-31 |
| 2026-03-31 | $28.71M 10-Q · filed 2026-05-06 | $69.86M derived: sum of 2 quarters · filed 2026-05-06 | $88.99M derived: sum of 3 quarters · filed 2026-05-06 | $88.01M derived: sum of 4 quarters · filed 2026-07-31 |
| 2025-12-31 | $41.15M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $60.29M derived: sum of 2 quarters · filed 2026-02-26 | $59.31M derived: sum of 3 quarters · filed 2026-07-31 | $66.35M 10-K · filed 2026-02-26 |
| 2025-09-30 | $19.14M 10-Q · filed 2025-11-05 | $18.16M derived: sum of 2 quarters · filed 2026-07-31 | $25.20M 10-Q · filed 2025-11-05 | $30.32M derived: sum of 4 quarters · filed 2026-07-31 |
| 2025-06-30 | -$980.00K 10-Q · filed 2026-07-31 | $6.07M 10-Q · filed 2026-07-31 | $11.18M derived: sum of 3 quarters · filed 2026-07-31 | $26.34M derived: sum of 4 quarters · filed 2026-07-31 |
| 2025-03-31 | $7.05M 10-Q · filed 2026-05-06 | $12.16M derived: sum of 2 quarters · filed 2026-05-06 | $27.32M derived: sum of 3 quarters · filed 2026-05-06 | $33.05M derived: sum of 4 quarters · filed 2026-05-06 |
| 2024-12-31 | $5.11M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $20.27M derived: sum of 2 quarters · filed 2026-02-26 | $26.00M derived: sum of 3 quarters · filed 2026-02-26 | $24.14M 10-K · filed 2026-02-26 |
| 2024-09-30 | $15.15M 10-Q · filed 2025-11-05 | $20.89M derived: sum of 2 quarters · filed 2025-11-05 | $19.02M 10-Q · filed 2025-11-05 | -$9.27M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-06-30 | $5.73M 10-Q · filed 2025-08-07 | $3.87M 10-Q · filed 2025-08-07 | -$24.42M derived: sum of 3 quarters · filed 2026-02-26 | -$54.04M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-03-31 | -$1.86M 10-Q · filed 2025-05-08 | -$30.16M derived: sum of 2 quarters · filed 2026-02-26 | -$59.77M derived: sum of 3 quarters · filed 2026-02-26 | -$68.18M derived: sum of 4 quarters · filed 2026-02-26 |
| 2023-12-31 | -$28.29M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | -$57.91M derived: sum of 2 quarters · filed 2026-02-26 | -$66.31M derived: sum of 3 quarters · filed 2026-02-26 | -$74.40M 10-K · filed 2026-02-26 |
| 2023-09-30 | -$29.62M 10-Q · filed 2024-11-07 | -$38.02M derived: sum of 2 quarters · filed 2024-11-07 | -$46.11M 10-Q · filed 2024-11-07 | |
| 2023-06-30 | -$8.40M 10-Q · filed 2024-08-07 | -$16.49M 10-Q · filed 2024-08-07 | ||
| 2022-12-31 | -$36.56M 10-K · filed 2025-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Celcuity Inc. (CELC) | United States | $3.887B | -22.62 |
| CareDx, Inc. (CDNA) | United States | $3.174B | 13.21 |
| GRAIL, Inc. (GRAL) | United States | $5.591B | -7.78 |
| RadNet, Inc. (RDNT) | United States | $5.611B | -229.65 |
| Fortrea Holdings Inc. (FTRE) | United States | $1.903B | -19.43 |
| Personalis, Inc. (PSNL) | United States | $1.769B | -13.30 |
| CASTLE BIOSCIENCES INC (CSTL) | United States | $1.074B | -37.45 |
| Lumexa Imaging Holdings, Inc. (LMRI) | United States | $0.951B | |
| Fulgent Genetics, Inc. (FLGT) | United States | $0.593B | -6.70 |
| BIODESIX INC (BDSX) | United States | $0.312B |